Joanna Canham

413 total citations
19 papers, 150 citations indexed

About

Joanna Canham is a scholar working on Hematology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Joanna Canham has authored 19 papers receiving a total of 150 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 6 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joanna Canham's work include Acute Myeloid Leukemia Research (11 papers), Gastric Cancer Management and Outcomes (5 papers) and Esophageal Cancer Research and Treatment (5 papers). Joanna Canham is often cited by papers focused on Acute Myeloid Leukemia Research (11 papers), Gastric Cancer Management and Outcomes (5 papers) and Esophageal Cancer Research and Treatment (5 papers). Joanna Canham collaborates with scholars based in United Kingdom, Denmark and United States. Joanna Canham's co-authors include David Sebag‐Montefiore, Simon Gollins, Somnath Mukherjee, Andrew Bateman, Tom Crosby, M. Hawkins, Sarah Gwynne, Heike I. Grabsch, Chris Hurt and Ganesh Radhakrishna and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

Joanna Canham

15 papers receiving 148 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joanna Canham United Kingdom	5	71	68	47	27	21	19	150
F. Petruzzelli Italy	6	94 1.3×	16 0.2×	28 0.6×	7 0.3×	15 0.7×	11	174
Tomasz Ociepa Poland	8	15 0.2×	14 0.2×	43 0.9×	25 0.9×	49 2.3×	28	136
M. El Khorassani Morocco	7	10 0.1×	61 0.9×	43 0.9×	17 0.6×	19 0.9×	25	132
Manolis Papadakis Greece	7	124 1.7×	98 1.4×	28 0.6×	4 0.1×	6 0.3×	7	176
Shashikant Apte India	9	14 0.2×	32 0.5×	146 3.1×	14 0.5×	9 0.4×	31	198
Katell Le Dû France	6	17 0.2×	40 0.6×	7 0.1×	8 0.3×	13 0.6×	20	124
Allison L. Hunt United States	5	25 0.4×	13 0.2×	8 0.2×	11 0.4×	10 0.5×	17	108
Elie A Akl Malaysia	2	31 0.4×	16 0.2×	21 0.4×	6 0.2×	3 0.1×	2	129
Lajos Mátyás Hungary	6	178 2.5×	25 0.4×	30 0.6×	16 0.6×	4 0.2×	6	266
Maria Michelagnoli United Kingdom	7	20 0.3×	65 1.0×	10 0.2×	21 0.8×	26 1.2×	14	132

Countries citing papers authored by Joanna Canham

Since Specialization

Citations

This map shows the geographic impact of Joanna Canham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joanna Canham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joanna Canham more than expected).

Fields of papers citing papers by Joanna Canham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joanna Canham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joanna Canham. The network helps show where Joanna Canham may publish in the future.

Co-authorship network of co-authors of Joanna Canham

This figure shows the co-authorship network connecting the top 25 collaborators of Joanna Canham. A scholar is included among the top collaborators of Joanna Canham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joanna Canham. Joanna Canham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Russell, Nigel H., Jad Othman, Oliver Cumming, et al.. (2025). Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 -mutated AML. Blood Advances. 9(24). 6455–6466.

Evans, Mererid, Chris Hurt, Abhishek Mahajan, et al.. (2025). Correlation between imaging-detected and pathological extranodal extension in a randomised trial in Human Papillomavirus-positive oropharyngeal cancer. British Journal of Cancer. 134(3). 428–438.

Othman, Jad, Nicola Potter, Adam Ivey, et al.. (2024). Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood. 143(19). 1931–1936. 33 indexed citations

Mehta, Priyanka, Thomas Wagner, Stefan Faderl, et al.. (2024). A Randomized Comparison of CPX-351 and FLAG-Ida in Patients with High-Risk Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) and MDS-Related Gene Mutations: A Subgroup Analysis of the UK NCRI AML19 Trial. Blood. 144(Supplement 1). 55–55. 1 indexed citations

Othman, Jad, Nicola Potter, Jelena Jovanović, et al.. (2024). Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements - Experience from UK NCRI AML17 and AML19. Blood. 144(Supplement 1). 845–845.

Canham, Joanna, Angela Casbard, Sylvie Freeman, et al.. (2024). Optimising Therapy in FLT3-Mutated Acute Myeloid Leukaemia. Blood. 144(Supplement 1). 4191.1–4191.1.

O’Hara, James, Chris Hurt, Joanne Patterson, et al.. (2024). Transoral Laser or Robotic Surgery Outcomes for Oropharyngeal Carcinoma. JAMA Otolaryngology–Head & Neck Surgery. 150(11). 1002–1002. 2 indexed citations

Russell, Nigel H., Jad Othman, Richard Dillon, et al.. (2023). S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL. HemaSphere. 7(S3). e252478c–e252478c. 1 indexed citations

Othman, Jad, Nicola Potter, Adam Ivey, et al.. (2023). The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies. Blood. 142(Supplement 1). 425–425. 3 indexed citations

10.

Russell, Nigel H., Oliver Cumming, Jad Othman, et al.. (2023). P484: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL. HemaSphere. 7(S3). e13145db–e13145db. 1 indexed citations

11.

Russell, Nigel H., Charlotte S. Wilhelm-Benartzi, Steven Knapper, et al.. (2022). FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial. Blood. 140(Supplement 1). 526–528. 4 indexed citations

12.

Russell, Nigel H., Charlotte S. Wilhelm-Benartzi, Jad Othman, et al.. (2022). S126: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. RESULTS FROM THE NCRI AML19 “MIDOTARG” PILOT TRIAL. HemaSphere. 6. 27–28. 2 indexed citations

13.

Othman, Jad, Richard Dillon, Charlotte S. Wilhelm-Benartzi, et al.. (2022). Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial. Blood. 140(Supplement 1). 1036–1038. 2 indexed citations

14.

Mukherjee, Somnath, Chris Hurt, Ganesh Radhakrishna, et al.. (2021). Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. European Journal of Cancer. 153. 153–161. 13 indexed citations

15.

Mukherjee, Somnath, Chris Hurt, Catrin Cox, et al.. (2020). Induction oxaliplatin capecitabine followed by switch to carboplatin-paclitaxel based RT versus continuing oxaliplatin capecitabine RT in operable esophageal adenocarcinoma: Survival analysis of the randomized phase II neoscope trial.. Journal of Clinical Oncology. 38(4_suppl). 373–373. 3 indexed citations

16.

Mukherjee, Somnath, Chris Hurt, Sarah Gwynne, et al.. (2017). NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. European Journal of Cancer. 74. 38–46. 32 indexed citations

17.

Mukherjee, Somnath, Chris Hurt, Sarah Gwynne, et al.. (2016). NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine (OXCAP) or carboplatin/paclitaxel (CarPac) based chemoradiation (CRT) as pre-operative regimen for resectable oesophageal adenocarcinoma.. Journal of Clinical Oncology. 34(4_suppl). 3–3. 3 indexed citations

18.

Noble, Simon, Annmarie Nelson, David Fitzmaurice, et al.. (2015). A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT). Health Technology Assessment. 19(83). 1–94. 25 indexed citations

19.

Mukherjee, Somnath, Chris Hurt, Sarah Gwynne, et al.. (2015). NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. BMC Cancer. 15(1). 48–48. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact